Your browser doesn't support javascript.
loading
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Pfestroff, A; Luster, M; Jilg, C A; Olbert, P J; Ohlmann, C H; Lassmann, M; Maecke, H R; Ezziddin, S; Bodei, L.
Affiliation
  • Pfestroff A; Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
  • Luster M; Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany. luster@med.uni-marburg.de.
  • Jilg CA; Department of Urology, University Hospital Freiburg, Freiburg, Germany.
  • Olbert PJ; Department of Urology, University Hospital Marburg, Marburg, Germany.
  • Ohlmann CH; Department of Urology, Saarland University Hospital, Homburg/Saar, Germany.
  • Lassmann M; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Maecke HR; Department of Nuclear Medicine and Radiopharmacy, University Hospital Freiburg, Freiburg, Germany.
  • Ezziddin S; Department of Nuclear Medicine, Saarland University Hospital, Homburg/Saar, Germany.
  • Bodei L; Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
Eur J Nucl Med Mol Imaging ; 42(13): 1971-5, 2015 Dec.
Article in En | MEDLINE | ID: mdl-26373947

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiopharmaceuticals / Glutamate Carboxypeptidase II / Prostatic Neoplasms, Castration-Resistant Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2015 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiopharmaceuticals / Glutamate Carboxypeptidase II / Prostatic Neoplasms, Castration-Resistant Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2015 Type: Article Affiliation country: Germany